Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
NeuBase Therapeutics, Inc. (OHRP)
|
Add to portfolio |
|
|
|
| Price: |
$6.23
| | Metrics |
| OS: |
2.36
|
M
| |
-174
|
% ROE
|
| Market cap: |
$14.7
|
M
| |
-887
|
% ROIC
|
|
Net cash:
|
$14.7
|
M
| |
$6.24
|
per share
|
|
EV:
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($18.7)
|
M
| |
|
|
|
EBIT
|
($19.5)
|
M
| |
|
|
| EPS |
($2.53)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Sep-30-22 | Sep-30-21 | Sep-30-20 | Sep-30-19 | Sep-30-18 | Sep-30-17 | Sep-30-16 | Sep-30-15 |
| Revenues | 0.0 | 0.0 | 0.0 | 0.0 | 1.2 | 0.1 | 49.9 | 0.0 |
| Revenue growth | | | | -100.0% | 1636.7% | -99.9% | | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | 0.0 | 0.0 | 0.0 | 1.2 | 0.1 | 49.9 | 0.0 |
| Gross margin | | | | | 100.0% | 100.0% | 100.0% | |
| Selling, general and administrative | | | | | | | | |
| Research and development | 21.4 | 11.5 | 6.9 | 3.4 | 4.3 | 17.4 | 16.5 | 8.8 |
| General and administrative | 11.9 | 12.2 | 10.1 | 9.1 | 3.6 | 5.3 | 7.7 | 7.5 |
| EBITA | -33.7 | -26.8 | -17.3 | -25.4 | -6.7 | -22.7 | 24.5 | -13.6 |
| EBITA margin | | | | | -548.1% | -32024.3% | 49.2% | |
| Amortization of intangibles | | | | 0.1 | 1.1 | 1.1 | 1.1 | 1.1 |
| EBIT | -33.7 | -26.8 | -17.3 | -25.5 | -7.8 | -23.8 | 23.4 | -14.7 |
| EBIT margin | | | | | -638.8% | -33608.1% | 46.9% | |
| Pre-tax income | -33.8 | -25.4 | -17.4 | -26.1 | -26.5 | -47.6 | -25.8 | -15.2 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | -13.2 | -23.8 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 50.0% | 50.0% | 0.0% | 0.0% |
| Net income | -33.8 | -25.4 | -17.4 | -26.1 | -13.2 | -23.8 | -25.8 | -15.2 |
| Net margin | | | | | -1077.2% | -33651.8% | -51.6% | |
| |
| Diluted EPS | ($1.04) | ($0.93) | ($0.89) | ($3.16) | ($0.23) | ($0.53) | ($0.82) | ($0.54) |
| Shares outstanding (diluted) | 32.5 | 27.3 | 19.6 | 8.3 | 56.4 | 44.8 | 31.3 | 28.4 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|